Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Pipeline Review, H2 2018
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Pipeline Review, H2 2018
SUMMARY
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2018, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Depression, Lymphoma, Multiple Myeloma (Kahler Disease), Parkinson's Disease, Acute Lung Injury, Breast Cancer, Colon Cancer, Idiopathic Pulmonary Fibrosis, Inflammation, Leukemias, Lung Cancer, Nerve Injury, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Sarcomas, Solid Tumor and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2018, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Depression, Lymphoma, Multiple Myeloma (Kahler Disease), Parkinson's Disease, Acute Lung Injury, Breast Cancer, Colon Cancer, Idiopathic Pulmonary Fibrosis, Inflammation, Leukemias, Lung Cancer, Nerve Injury, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Sarcomas, Solid Tumor and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
- The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
AbbVie Inc
Angelini Group
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles
AU-4869 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit NAMPT for Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enamptcumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-9274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-3154567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-82 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P7-C3A20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STF-118804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting
Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting
Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
Aug 01, 2016: Pharmatek, a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies
Jun 27, 2016: OncoTartis: Initiated OT-82 GLP Toxicology and Safety Pharmacology studies
Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting
Mar 15, 2016: OncoTartis Provides Update on OT-82
Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015
Mar 30, 2015: Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research initiated testing of OT-82
Oct 30, 2014: OncoTartis Provides Update on Toxicology study of OT-82
May 16, 2014: Nanosyn, a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale
Nov 01, 2013: Novel drug discovery method designed by Stanford scientists
Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
AbbVie Inc
Angelini Group
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles
AU-4869 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit NAMPT for Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enamptcumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-9274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-3154567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-82 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P7-C3A20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STF-118804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting
Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting
Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
Aug 01, 2016: Pharmatek, a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies
Jun 27, 2016: OncoTartis: Initiated OT-82 GLP Toxicology and Safety Pharmacology studies
Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting
Mar 15, 2016: OncoTartis Provides Update on OT-82
Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015
Mar 30, 2015: Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research initiated testing of OT-82
Oct 30, 2014: OncoTartis Provides Update on Toxicology study of OT-82
May 16, 2014: Nanosyn, a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale
Nov 01, 2013: Novel drug discovery method designed by Stanford scientists
Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Angelini Group, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by Calico LLC, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Karyopharm Therapeutics Inc, H2 2018
Pipeline by OncoTartis Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Angelini Group, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by Calico LLC, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Karyopharm Therapeutics Inc, H2 2018
Pipeline by OncoTartis Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AbbVie Inc
Angelini Group
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AbbVie Inc
Angelini Group
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
